Pancreatic CancerNCT00577564
EUS-CPN: A Retrospective Review
An observational study of Pancreatic Cancer, run by Indiana University at 1 site in United States.
Trial summary
The purpose of this retrospective study is to measure the safety of EUS-CPN in patients that have undergone this procedure in the last decade. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer
- How many people
- Not given
- Where
- 1 siteUnited States
- Study dates
- Jul 2006to Dec 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients that underwent a EUS-CPN over a ten year period at Indiana University Medical Center will be considered.
Who may be able to join
- Any subject that has undergone EUS-CPN will be considered for this study.
Who cannot join
- Subjects will be excluded if they have undergone a celiac plexus neurolysis (endoscopic, percutaneous, or surgical) at an another institution.
Trial locations and contacts
1 site in 1 country.
United States1 site
Clarian: University Hospital
Indianpolis, Indiana, 46202
About this study
Official title: Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN): A Retrospective Review of Safety
The purpose of this retrospective study is to measure the safety of EUS-CPN in patients that have undergone this procedure in the last decade.
- Conditions
- Pancreatic Cancer
- Medical subject headings
- Pancreatic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of EUS-CPN procedures for each patient
Measured: over a ten year period
Secondary outcomes (1)
Procedure-related complications
Measured: over a ten year period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2007 (estimated)
- Study startJul 2006
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Investigators
- Julia LeBlanc, MD, MPH, Principal investigator, Indiana University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00577564
- Sponsor's protocol ID
- 0606-59
- Other IDs
- IRB #0606-59
- Status last verified
- Sep 2012
- First submitted
- 19 Dec 2007
- Last updated
- 12 Sep 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN): A Retrospective Review of Safety
- ClinicalTrials.gov ID
- NCT00577564
- Acronym / sponsor ID
- 0606-59
- Conditions
- Pancreatic Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Study start
- Jul 2006
- Study completion
- Dec 2007 (actual)
- First posted
- 20 Dec 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this retrospective study is to measure the safety of EUS-CPN in patients that have undergone this procedure in the last decade.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients that underwent a EUS-CPN over a ten year period at Indiana University Medical Center will be considered.
Key inclusion criteria (1 listed)
- Any subject that has undergone EUS-CPN will be considered for this study.
Key exclusion criteria (1 listed)
- Subjects will be excluded if they have undergone a celiac plexus neurolysis (endoscopic, percutaneous, or surgical) at an another institution.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of EUS-CPN procedures for each patient
Time frame: over a ten year period
1 secondary outcome
Procedure-related complications
Time frame: over a ten year period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2012.
Related trials for Pancreatic Cancer
RecruitingPhase 3
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingObservational study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Solid Tumor, Adult, Colorectal Cancer
Active, not recruitingPhase 3
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julia LeBlanc, MD, MPH principal investigator
Indiana University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Sep 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of EUS-CPN procedures for each patient (time frame: over a ten year period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2012.